GVHD Prophylaxis

DRUG14 trials

Sponsors

Medical College of Wisconsin, National Cancer Institute (NCI), Columbia University, Masonic Cancer Center, University of Minnesota, Gruppo Italiano Trapianto di Midollo Osseo

Conditions

Acute Myelogenous LeukemiaAutoimmune LymphoproliferativeBurkitt LymphomaCommon Variable ImmunodeficiencyEngraftment SyndromeFollicular LymphomaFungal InfectionGraft Vs Host Disease

Phase 1

Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia

CompletedNCT01020539

Columbia UniversityAcute Myelogenous Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome

Start: 2002-09-11End: 2020-12-31Updated: 2021-08-06

Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT

TerminatedNCT03963024

IRCCS San RaffaeleGraft Vs Host Disease, Irradiated Bone Marrow, Leukemia, Acute +2

Start: 2014-02-12End: 2019-01-31Updated: 2020-10-19

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

RecruitingNCT05470491

National Cancer Institute (NCI)Hematologic Malignancies, HIV

Start: 2023-01-26End: 2027-07-30Target: 265Updated: 2026-04-01

Phase 2

Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)

TerminatedNCT00096460

Medical College of WisconsinFollicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma +1

Start: 2004-08-31End: 2009-03-31Updated: 2023-01-05

Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)

CompletedNCT00849147

Medical College of WisconsinBurkitt Lymphoma, Leukemia, Myeloid, Acute, Lymphoma, B-Cell +3

Start: 2008-10-31End: 2013-11-30Updated: 2023-01-04

Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)

CompletedNCT00864227

Medical College of WisconsinBurkitt Lymphoma, Leukemia, Myeloid, Acute, Lymphoma, B-Cell +3

Start: 2008-12-31End: 2013-11-30Updated: 2022-12-14

Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer

CompletedNCT00923845

National Cancer Institute (NCI)Engraftment Syndrome, Graft-Versus-Host Disease, Renal Cell Carcinoma

Start: 2008-03-01End: 2017-06-22Updated: 2017-09-29

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

RecruitingNCT02579967

National Cancer Institute (NCI)Autoimmune Lymphoproliferative, Common Variable Immunodeficiency, Immune System Diseases +2

Start: 2015-11-19End: 2036-12-31Target: 354Updated: 2026-03-27

Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT

CompletedNCT02988466

Masonic Cancer Center, University of MinnesotaHematologic Malignancies

Start: 2017-01-24End: 2025-03-24Updated: 2025-05-28

Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies

CompletedNCT03270748

Gruppo Italiano Trapianto di Midollo OsseoMyeloid Malignancies

Start: 2020-01-15End: 2022-11-20Updated: 2023-03-10

Peripheral Blood Allogenic Stem Cell Transplantation Using Non-anti Thymocyte Globulin Regimens in Severe Aplastic Anemia Patients

Assiut UniversitySevere Aplastic Anemia

Start: 2019-01-01End: 2020-06-30Target: 50Updated: 2018-11-27

Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole

CompletedNCT03434704

Ciceri FabioFungal Infection, Graft Vs Host Disease, Leukemia, Acute +2

Start: 2018-06-18End: 2019-10-13Updated: 2022-07-19

Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

Active, not recruitingNCT03663933

National Cancer Institute (NCI)Autoimmune Lymphoproliferative, Common Variable Immunodeficiency, Immune System Diseases +2

Start: 2018-09-04End: 2030-04-03Updated: 2026-03-17

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

RecruitingNCT03922724

National Cancer Institute (NCI)Immune System Diseases, Lymphoproliferative Disorders, Peripheral T-cell Lymphomas

Start: 2019-04-18End: 2030-10-31Target: 330Updated: 2026-03-30

Related Papers

Posttransplant cyclophosphamide as GVHD prophylaxis in patients receiving mismatched unrelated HCT: the PHYLOS trial

Blood Advances2025-02-105 citations

Understanding Barriers to Hematopoietic Cell Transplant (HCT) Access: Socio-Demographic Characteristics and Area Deprivation Index (ADI) of Patients Referred to the National Institutes of Health (NIH) for HCT

Blood2024-11-05

Projected Impact of Omidubicel-onlv on Racial/Ethnic Disparities in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Outcomes in Hematologic Malignancies.

2024-03-011 citations

BK Virus-Associated Hemorrhagic Cystitis in Allogeneic Hematopoietic Cell Transplantation (HCT) Recipients with Primary Immunodeficiency

Biology of Blood and Marrow Transplantation2020-01-23

Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.

2011-04-28422 citations